[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362230-105":59,"doc-detail-362230-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-genome-wide-genetic-screen-reveals-the-p2y2-integrin-axis-as-a-stabilizer-of-egfr-mutants-in-nonsmall-cell-lung-cancer-nsclc","A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)","","Activating EGFR mutations drive non–small cell lung cancer (NSCLC), where oncogenic EGFR mutants are ligand-independent and unusually stable, yet the stabilizing mechanism has been unclear. A genome-wide RNA interference screen identifies stabilizer genes required for mutant EGFR stability, highlighting the P2Y2 receptor (P2Y2). High extracellular ATP transactivates EGFR mutants through P2Y2 activation and Src-dependent phosphorylation, forming a P2Y2–integrin β1–EGFR complex enriched in endosomes. Disrupting this axis destabilizes EGFR mutants and suggests clinical relevance via elevated P2Y2 and integrin β1 in patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-genome-wide-genetic-screen-reveals-the-p2y2-integrin-axis-as-a-stabilizer-of-egfr-mutants-in-nonsmall-cell-lung-cancer-nsclc/362230/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-genome-wide-genetic-screen-reveals-the-p2y2-integrin-axis-as-a-stabilizer-of-egfr-mutants-in-nonsmall-cell-lung-cancer-nsclc/362230.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address about EGFR mutants in NSCLC?","Question",{"text":112,"@type":113},"Oncogenic EGFR mutants are ligand-independent and more stable, but the molecular mechanism that enables this stability remained unclear.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the stabilizer of mutant EGFR identified?",{"text":117,"@type":113},"A genome-wide RNA interference screen was used to find genes encoding cellular stabilizers responsible for EGFR mutant stability, with P2Y2 highlighted as a key stabilizer.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links extracellular ATP, P2Y2 activation, and mutant EGFR stability?",{"text":121,"@type":113},"High extracellular ATP activates P2Y2, which transactivates EGFR mutants; mutant EGFR stability is reinforced by forming a P2Y2–integrin β1–EGFR complex enriched in endosomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362230,1790810608,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","CANCER  \nA genome-wide genetic screen reveals the  \nP2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC)  \nYafei Du1,2†, Wenjing Wang1†‡, Hui Chin Goh1, Thamil Selvan Vaiyapuri1, Anandhkumar Raju1, Yu-Chun Hsiao3, Cheng Chun Wang1, Vanisha Agrawal1, Noorul Farzana Mohideen1, Norhidayah Binte Mohd Mazian1, Feride Karatekin1, Wendy Kehan Wang1,  \nManikandan Lakshmanan1, Komal Gupta1,4, Han Chang5,6, Xavier Le Guezennec1, Frederic Bard1,7, Daniel S. W. Tan4, Vinay Tergaonkar1, Mien-Chie Hung3, Xiaogang Liu2,8,  \nWanjin Hong1*, Gandhi T. K. Boopathy1*  \nActivating mutations in the epidermal growth factor receptor (EGFR) gene drive non–small cell lung cancer (NSCLC). Oncogenic EGFR mutants are ligand-independent and more stable, but the underlying mechanism remains unclear. We hypothesized that EGFR mutants selectively leverage cellular stabilizers to evade degradation. Genome-wide RNA interference screens identified genes (encoding for stabilizers) responsible for mutant EGFR stability, with P2Y2 receptor (P2Y2) emerging as a bona fide stabilizer. Mechanistically, high extracellular adenosine triphosphate (ATP) levels transactivate EGFR mutants via P2Y2 activation, previously shown to signal through Src kinase–dependent EGFR phosphorylation. Our study reveals that ATP-driven P2Y2 activation stabilizes EGFR mutants by forming a P2Y2-integrin β1-EGFR complex enriched in endosomes. Targeting this axis destabilizes EGFR mutants and offers a strategy against drug resistance. Elevated P2Y2 and integrin β1 expression in patients with NSCLC implies clinical relevance. Our results provide previously unidentified insight that EGFR mutants enhance extracellular ATP levels to activate P2Y2-integrin for enhanced stability of EGFR mutants to drive the oncogenic program.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. Distributed under a creative commons Attribution noncommercial license 4.0 (cc BY-nc) .  \nINTRODUCTION  \nLung cancer is the leading cause of cancer-related deaths globally (1). Around 85% of all lung cancer cases are attributed to non–small cell lung cancer (NSCLC) . Activating mutations in the epidermal growth factor receptor (EGFR) gene are detected in up to 40 to 60% of lung adenocarcinoma (a type of NSCLC) in Southeast Asia (2, 3) . The primary EGFR mutations, 19del and L858R, make up around 90% of all EGFR mutation–positive NSCLC tumors (4) and respond well to EGFR tyrosine kinase inhibitors (TKIs) (5–7). Although there have been notable breakthroughs in the development of TKI treatments, the emergence of acquired resistance to EGFR TKIs attributed to secondary and tertiary mutations, such asthe T790M mutation (8, 9) and C797X (10), respectively, contributes to treatment failure (11). Although several mechanisms can lead to acquired drug resistance to TKIs in NSCLC (12–15), the most common is resistant mutations  \n1institute of Molecular and cell Biology (iMcB), Agency for Science, technology and Research (A∗StAR), 61 Biopolis Drive, Proteos, Singapore 138673, Singapore. 2Department of chemistry, national University of Singapore, Singapore, Singapore. 3center for Molecular Medicine, Research center for cancer Biology, and Graduate institute of Biomedical Sciences, china Medical University, taichung, taiwan. 4 national cancer centre Singapore, 11 hospital crescent, Singapore 169610, Singapore. 5School of Medicine, china Medical University, taichung, taiwan. 6Department of Pathology, china Medical University hospital, taichung, taiwan. 7centre de Recherche en cancérologie de Marseille (cRcM), Aix Marseille Université, inserm, cnRS, institut Paoli-calmettes, equipe leader Fondation ARc 2021, Marseille, France. 8institute of Materials Research and engineering (iMRe), A*StAR, 2 Fusionopolis Way, Singapore 138634, Singapore.  \n*corresponding [author. email:](author. email:) [","cbCaidHkICWPhfts","https://ap.wps.com/l/cbCaidHkICWPhfts","pdf",5178187,23,"English","# Introduction\n## EGFR mutations and NSCLC background\n## Acquired resistance to EGFR TKIs\n## Rationale and genome-wide siRNA screen approach\n## Focus on P2Y2 and stabilizer mechanisms","[{\"question\":\"What problem does the study address about EGFR mutants in NSCLC?\",\"answer\":\"Oncogenic EGFR mutants are ligand-independent and more stable, but the molecular mechanism that enables this stability remained unclear.\"},{\"question\":\"How was the stabilizer of mutant EGFR identified?\",\"answer\":\"A genome-wide RNA interference screen was used to find genes encoding cellular stabilizers responsible for EGFR mutant stability, with P2Y2 highlighted as a key stabilizer.\"},{\"question\":\"What mechanism links extracellular ATP, P2Y2 activation, and mutant EGFR stability?\",\"answer\":\"High extracellular ATP activates P2Y2, which transactivates EGFR mutants; mutant EGFR stability is reinforced by forming a P2Y2–integrin β1–EGFR complex enriched in endosomes.\"}]","A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non–small cell lung cancer (NSCLC) | PDF",1790146853,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/834b9ca7dd7308e803d10ce0da3c3c04.webp",983,1250,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/44a82ffec57f0dc12f8e7d0dd1c4424a.webp",982,1249,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5fa39389c2edabd0a20308dfa579d71.webp",981,1248,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00e35a608e354a484240bae58e9af337.webp",980,1247]